[Prevalence of hepatocellular carcinoma in cirrhotic patients with with portosystemic shunt. Cohort analysis]

Gastroenterol Hepatol. 1996 Apr;19(4):189-93.
[Article in Spanish]


The development of hepatocellular carcinoma is frequent in patients with hepatic cirrhosis of any etiology. Despite the suggestion that portosystemic shunt may increase the risk of developing this neoplasm there are scarce clinical evidence to confirm this suggestion. The present cohort study was aimed at analyzing the follow up data of 232 patients included in 3 prospective randomized controlled studies in which the efficacy of shunt procedures (group I: portocaval or splenorenal anastomosis) versus techniques other than shunt (group II: esophageal transection or variceal sclerosis) in the treatment of upper-6I bleeding secondary to rupture of esophageal-gastric varices were compared. After a mean follow up of 50 months, no differences were observed between the two groups in relation with the prevalence of hepatocellular carcinoma (group I: 17%; group II: 12%; relative risk: 1.41 [CI 95%: 0.72 - 2.75]; p = 0.41) or the actuarial probability of developing this neoplasm (group I: 2% at 2 years, 21% at 5 years; group II: 7% at 2 years, 14% at 5 years; p = 0.42). The results of this analysis suggest that the performance of portosystemic shunt does not increase the risk of developing hepatocellular carcinoma in patients with hepatic cirrhosis.

Publication types

  • Clinical Trial
  • Comparative Study
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Hepatocellular / epidemiology*
  • Cohort Studies
  • Cross-Sectional Studies
  • Esophageal and Gastric Varices / surgery
  • Esophageal and Gastric Varices / therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Liver Cirrhosis / complications*
  • Liver Neoplasms / epidemiology*
  • Male
  • Middle Aged
  • Portasystemic Shunt, Surgical / adverse effects*
  • Probability
  • Prospective Studies
  • Sclerotherapy
  • Splenorenal Shunt, Surgical / adverse effects
  • Time Factors